Acquisition of Freeline by Syncona Becomes Effective
LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq:FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement (the “Scheme”), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the “Scheme Circular”) has been delivered to the Registrar of Companies. Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited.